Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Clinical Medicine|October 5, 2019
Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin UsersKi-Chul Sung, Ji Hye Huh, Seungho Ryu, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 3, 2018
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trialAntigoni Manousopoulou, Eleonora Scorletti, Debbie E Smith, et al.
Food Research International (Ottawa, Ont.)|January 21, 2020
In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteriaFernanda C Henrique-Bana, Xuedan Wang, Giselle N Costa, et al.
Journal of Visualized Experiments : Jove|May 7, 2019
Rapid Lipid Droplet Isolation Protocol Using a Well-established Organelle Isolation KitJascha Brettschneider, Jason M Correnti, Chelsea Lin, et al.
Journal of Hepatology|August 15, 2015
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trialEleonora Scorletti, Annette L West, Lokpal Bhatia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 27, 2017
Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLDValerio Nobili, Anna Alisi, Antonella Mosca, et al.
Molecular Metabolism|September 15, 2023
Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulationSookyoung Jeon, Eleonora Scorletti, Joseph Dempsey, et al.
Metabolism: Clinical and Experimental|December 15, 2023
Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLDJosh Bilson, Carolina J Oquendo, James Read, et al.
JHEP Reports : Innovation in Hepatology|December 17, 2024
Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approachHelen Ye Rim Huang, Cecilia Vitali, David Zhang, et al.
Hepatology Communications|April 26, 2024
A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipidsLeonida Hehl, Kate T Creasy, Cecilia Vitali, et al.
Pageof 6